RxDoctor Payments Data

David Sayah, MD

Pulmonary Disease · Los Angeles, CANPI 1023288719

Payments from drug & device makers

$63,963in general payments, 2019–2025

Across 61 payments — averaging $1048.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$41K
  • Mallinckrodt Hospital Products Inc.$22K
  • Tepha Inc$379
  • Abiomed$125
  • Grifols USA, LLC$125
  • AbbVie$91
  • plus $52 from 3 others

What the payments were for

  • Consulting fees$9,10014%
  • Speaking & faculty fees$35,99756%
  • Travel & lodging$17,40027%
  • Food & beverage$1,4302%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,963 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$63,159
Medicare patients
122
Services billed
727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrevymisLetermovir76$591,982
CresembaIsavuconazonium Sulfate68$419,396
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5022$205,012
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$50,464
Posaconazole45$43,852
EliquisApixaban24$29,296
Valganciclovir Hcl95$23,801
VraylarCariprazine Hcl12$16,458
Sirolimus39$16,102
Atovaquone33$15,545
Tacrolimus93$15,036
ZarxioFilgrastim-Sndz13$12,015
Mycophenolate Mofetil46$5,801
MotegrityPrucalopride Succinate12$5,436
Arnuity ElliptaFluticasone Furoate18$4,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$125$50,46412 claims
AbbVieVraylar$91$16,45812 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$41,267$5,43612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →